+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Regeneron Pharmaceuticals Inc - logo

Regeneron is a biotechnology company with its headquarters in New York City. Their product portfolio includes Praluent, Eylea and Arcalyst. Regeneron is a key player in research and development including drug discovery, human antibody technologies and genomics. Regeneron scientists focus on discovering new drug targets and developing effective product candidates through the proprietary VelociSuite platform of genetic technologies. In 2015 Regeneron announced a new collaboration with Sanofi to develop immuno-oncology treatments with a plan to begin clinical trials in 2016.

Fianlimab (REGN3767) Emerging Drug Insight and Market Forecast - 2035 - Product Thumbnail Image

Fianlimab (REGN3767) Emerging Drug Insight and Market Forecast - 2035

  • Drug Pipelines
  • December 2022
  • 30 Pages
  • Global
From
Extractables and Leachables Testing Services Market, 2018-2028 - Product Thumbnail Image

Extractables and Leachables Testing Services Market, 2018-2028

  • Report
  • September 2018
  • 200 Pages
  • Global
From
Fasinumab Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Fasinumab Emerging Drug Insight and Market Forecast - 2032

  • Report
  • August 2022
  • 30 Pages
  • Global
From
Retinopathy Of Prematurity - Pipeline Review, H2 2020 - Product Thumbnail Image

Retinopathy Of Prematurity - Pipeline Review, H2 2020

  • Drug Pipelines
  • September 2020
  • 68 Pages
  • Global
From
Cancer Therapeutics Market Report and Forecast 2023-2031 - Product Thumbnail Image

Cancer Therapeutics Market Report and Forecast 2023-2031

  • Report
  • April 2023
  • 147 Pages
  • Global
From
Rhinosinusitis Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update - Product Thumbnail Image

Rhinosinusitis Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update

  • Report
  • December 2022
  • 279 Pages
  • Global
From
Hypercholesterolemia Treatment Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Hypercholesterolemia Treatment Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • May 2023
  • 82 Pages
  • Global
From
Homozygous Familial Hypercholesterolemia Treatment Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Homozygous Familial Hypercholesterolemia Treatment Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • May 2023
  • 83 Pages
  • Global
From
Clinical Trials Sector Scorecard, Q2 2022 Update - Thematic Research - Product Thumbnail Image

Clinical Trials Sector Scorecard, Q2 2022 Update - Thematic Research

  • Report
  • June 2022
  • 16 Pages
  • Global
From
Eosinophilic Esophagitis - Pipeline Review, H2 2020 - Product Thumbnail Image

Eosinophilic Esophagitis - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 151 Pages
  • Global
From
Optic Neuropathy Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Optic Neuropathy Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • May 2023
  • 80 Pages
  • Global
From
Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes in Q2 2022 - Thematic Research - Product Thumbnail Image

Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes in Q2 2022 - Thematic Research

  • Report
  • July 2022
  • 25 Pages
  • Global
From
Keloids Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Keloids Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • November 2022
  • 43 Pages
  • Global
From
Bullous Pemphigoid Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Bullous Pemphigoid Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • November 2022
  • 55 Pages
  • Global
From
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 60 Pages
  • Global
From
Familial Amyloid Neuropathies Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Familial Amyloid Neuropathies Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 59 Pages
  • Global
From
Pigmented Villonodular Synovitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Pigmented Villonodular Synovitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • October 2022
  • 32 Pages
  • Global
From
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • September 2022
  • 168 Pages
  • Global
From
Stroke - Pipeline Review, H2 2020 - Product Thumbnail Image

Stroke - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 773 Pages
  • Global
From
Eosinophilic Esophagitis - Opportunity Assessment and Forecast to 2030 - Product Thumbnail Image

Eosinophilic Esophagitis - Opportunity Assessment and Forecast to 2030

  • Report
  • December 2021
  • 83 Pages
  • Global
From
Loading Indicator